

Measuring the value and effectiveness of ventricular assist device therapy in the Australian health care setting

Roslyn A. Prichard
RN, CNS, Post Grad. Dip CCU/ ICU

Thesis submitted in fulfilment of the requirements for
the degree of Doctor of Philosophy under the supervision of
Professors Christopher Hayward and Patricia Davidson

University of Technology Sydney
Faculty of Health

January 2020

Certificate of Original Authorship

I, *Roslyn Prichard* declare that this thesis, is submitted in fulfilment of the requirements for the award of Doctor of Philosophy, in the Health Faculty at the University of Technology Sydney.

This thesis is wholly my own work unless otherwise referenced or acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

This document has not been submitted for qualifications at any other academic institution.

This research was supported through an Australian Government Research Training Program scholarship, and a National Health and Medical Research Council, postgraduate scholarship.

Author signature

Production Note:

Signature removed prior to publication.

(Roslyn Prichard)

Date 01/09/2020

Word Count: 48,758

1.1 Acknowledgements:

No (wo) man is an island. ¹

Professors Christopher Hayward and Patricia Davidson have with patience and kindness over many years assisted with the processes and commiserated through the pitfalls of producing this PhD.

Professor Phillip Newton introduced me to the finer points of statistical analysis in excel, and thesis formatting. Professor Stephen Goodall gave me a place to be among the brightest and kindest of health economists at CHERE.

Lai Mun Balnave and Melita Howes with the finance team at St Vincent's hospital provided guidance in the use of data from the hospital information systems and Louise Kershaw assisted with the management and treatment of the financial data. Kate Richardson assisted with pharmacy cost data and Joseph Mouque provided the line drawings of the impella for the chapter frontispieces, and assistance with the design of the patient pathway.

My family and friends have supported me on this long road, no questions asked, buoying me up with their love and belief. Most especially I acknowledge the support and love that has kept me sane every day of this journey-my best beloved Sal (and Fleagle!)

¹ Adapted from *Devotions upon Emergent Occasions*.

John Donne 1624

1.2 Anthology of publications and presentations:

1.2.1 Publications associated with this thesis

Prichard R et al. Left Ventricular Device Implantation Impacts on Hospitalisation Rates, Length of Stay and Out of Hospital Time. *Heart, Lung and Circulation* (2018) Volume 27, Issue 6, Pages 708-715.

Prichard R et al. Combining institutional and administrative data to assess hospital costs for patients receiving ventricular assist devices. *International Journal of Technology Assessment in Health Care*. (2018).34(6):555-566

Prichard R, et al. Costs Before and After Left Ventricular Assist Device Implant and Preceding Heart Transplant: A Cohort Study. *Heart, Lung and Circulation* (2019), *In Press*

Prichard R, et al. Examining discrepancies between clinician proxy estimates and patient reported quality of life in heart failure: *Circulation: Cardiovascular Quality and Outcomes*. 17/09/2019. *Submitted* manuscript ID: CIRCCQO/2019/006160

NB: Published papers in PDF format (N=4) are attached as Appendices 1-4

1.2.2 Accepted abstracts for oral presentation as part of this thesis

Prichard et al. Impact of left VAD implantation on hospitalisation, and readmissions using a linked administrative dataset: *Cardiac Society of Australia and New Zealand. Adelaide August 2016. Heart, Lung and Circulation -Volume 25: S114*

Prichard et al. Frailty and quality of life in advanced heart failure and transplant medicine- do we need to screen? *Cardiac Society of Australia and New Zealand. Brisbane August 2018. Heart, Lung and Circulation -Volume 27: S101*

Prichard et al. Mind the gap: Clinician perceptions of quality of life in advanced heart failure. What are we missing? *Cardiac Society of Australia and New Zealand. Brisbane August 2019. Heart, Lung and Circulation -Volume 28: Supplement 4, S182*

NB: Abstracts accepted for oral presentation (N=3) are attached as Appendix 8

1.2.3 Abstracts accepted for poster presentation as part of this thesis

Prichard et al, Bottom-up costing ventricular assist device therapy and Optimal medical management- first Steps to establishing cost effectiveness. *Quality of Care and Clinical Outcomes conference*.

Baltimore, USA June 2014 *Circulation: Cardiovascular Quality and Outcomes*. 2014;7:A253

https://www.ahajournals.org/doi/abs/10.1161/circoutcomes.7.suppl_1.253

Prichard et al, Establishing institutional costs in the year before and after VAD implant and before heart transplant. *International Society for Heart and Lung Transplantation*. **Washington, DC, USA April 2016,**

The Journal of Heart and Lung Transplantation, Volume 35, Issue 4, Supplement, Page S272

[https://www.jhltonline.org/article/S1053-2498\(16\)00820-2/fulltext](https://www.jhltonline.org/article/S1053-2498(16)00820-2/fulltext)

Prichard et al: *International conference on Frailty & Sarcopenia Research, Barcelona, Spain 2017 The Journal of Frailty and Ageing V6: S235,*

Prichard et al, Quality of life in advanced heart failure- disconnect between patients' and clinicians' perceptions, independent of clinician experience: *European Society of Cardiology-Heart Failure*

Congress, Paris , France August 2017. European Journal of Heart Failure Volume 19 Supplement. S1, P 1049

Prichard et al, Frailty is associated with reduced patient reported quality of life in advanced heart failure patients and clinicians are poor at identifying it: *Annual Meeting of the Australian and New Zealand*

Society for Sarcopenia and Frailty Research (ANZSSFR), Adelaide November 2017 Australasian Journal on Ageing 2018, Volume 37: Issue S1 P54 <https://onlinelibrary.wiley.com/doi/10.1111/ajag.12508>

Prichard et al, Estimating Quality of Life among advanced heart failure patients: What could formal screening add to clinical assessments: *Cardiac Society of Australia and New Zealand*. **Brisbane August**

2018. Heart, Lung and Circulation -Volume 27: Supplement 2, S384

Prichard et al, Estimating quality of life in advanced heart failure- Can we differentiate excellent clinician proxies: *International Society for Pharmacoeconomic and Outcomes Research. Asia Pacific- Tokyo*
September 2018, *Value in Health* Volume 21, Supplement 2, S32

NB: Abstracts accepted for poster presentation (N=7) are attached as Appendix 9

1.3 Awards granted as part of this thesis

1. Cardiac Society of Australia and New Zealand (CSANZ) Heart Failure Council Henry Krum memorial Travel Grant/ ECS Heart Failure (2018)
2. National Health and Medical Research Council Postgraduate scholarship, Dora Lush Stipend (2017)
3. UTS Business school research grant (2016)
4. Health Services and Practice Research Student Development Award (HSP)
5. Health Faculty travel and research Grant

1.4 Table of Contents:

Table of Contents

1.1	ACKNOWLEDGEMENTS:.....	III
1.2	ANTHOLOGY OF PUBLICATIONS AND PRESENTATIONS:	IV
1.2.1	<i>Publications associated with this thesis</i>	<i>iv</i>
1.2.2	<i>Accepted abstracts for oral presentation as part of this thesis.....</i>	<i>v</i>
1.2.3	<i>Abstracts accepted for poster presentation as part of this thesis</i>	<i>vi</i>
1.3	AWARDS GRANTED AS PART OF THIS THESIS.....	VIII
1.4	TABLE OF CONTENTS:	IX
1.5	LIST OF TABLES:.....	XVI
1.6	LIST OF FIGURES	XVII
1.7	LIST OF APPENDICES:	XVIII
1.8	ACRONYMS AND ABBREVIATIONS:.....	XIX
1.10	ABSTRACT:	XXIII
	Study 1: Methods:	xxiv
	Study 2: Hospitalisation:	xxiv
	Study 3: Costs:.....	xxiv
	Study 4: Proxy Quality of Life:	xxiv
1.10.2	<i>Implications for policy, practice, education and research.....</i>	<i>xxiv</i>
CHAPTER 1	THE PRICE OF EVERYTHING AND THE VALUE OF NOTHING.	3
1.1	INTRODUCTION:	3
1.2	RESEARCH QUESTIONS:	4
1.3	PREVALENCE AND BURDEN OF HEART FAILURE.....	4
1.4	HEART TRANSPLANTATION	7
1.5	VENTRICULAR ASSIST DEVICES.....	7
1.6	THE AUSTRALIAN HEALTH CARE MILIEU.....	9

1.7	ECONOMIC EVALUATION IN HEALTH CARE.	12
1.8	PROBLEM STATEMENT	13
1.9	STRUCTURE OF THE THESIS	14
1.10	SIGNIFICANCE AND INNOVATION:	14
1.11	SUMMARY	15
1.12	REFERENCES:	17
 CHAPTER 2 SOURCES OF COST AND QUALITY OF LIFE DATA USED IN ECONOMIC ANALYSES OF VENTRICULAR DEVICE THERAPY.		21
2.1	INTRODUCTION:	21
2.2	METHODS:	22
2.3	RESULTS:	30
2.3.1	<i>Effectiveness data:</i>	30
2.3.2	<i>Utility data:</i>	31
2.3.3	<i>Cost data:</i>	32
	Gross and micro-costing:.....	32
	Top down and bottom-up approaches:	33
	Patient level data:	34
	Administrative data.....	35
	Cost-adjusted charges or total reimbursement:	35
	Diagnosis related groups (DRGs):.....	36
2.4	DISCUSSION:	37
2.4.1	<i>Incremental and opportunity costs:</i>	38
2.5	CONCLUSION:	39
2.6	REFERENCES:	40
 CHAPTER 3 COMBINING INSTITUTIONAL AND ADMINISTRATIVE DATA TO ASSESS HOSPITAL COSTS FOR PATIENTS RECEIVING VENTRICULAR ASSIST DEVICES:		47
3.1	CHAPTER INTRODUCTION.....	47
	What does the paper add to existing knowledge?.....	47

	What insights does the paper provide for informing health care-related decision-making?.....	48
3.2	ABSTRACT:	49
	Objectives:	49
	Methods:.....	49
	Results:.....	49
	Conclusions:	49
3.3	INTRODUCTION:	49
3.4	OBJECTIVES:	52
3.5	METHOD:	54
3.5.1	<i>Setting and sample:</i>	55
3.5.2	<i>Data collection, linkage and costing:</i>	55
3.5.3	<i>Clinician interviews:</i>	56
3.5.4	<i>Linked administrative data:</i>	63
3.5.5	<i>Statistical considerations:</i>	64
3.5.6	<i>Data extraction and quality control:</i>	66
3.5.7	<i>Missing data:</i>	67
3.6	RESULTS:	69
3.7	DISCUSSION:	69
3.7.1	<i>Limitations:</i>	71
3.8	CONCLUSIONS:	72
3.9	CHAPTER CONCLUSION:.....	72
3.10	REFERENCES:	74
CHAPTER 4 LEFT VENTRICULAR DEVICE IMPLANTATION IMPACTS ON HOSPITALISATION RATES, LENGTH OF STAY AND OUT OF HOSPITAL TIME		79
4.1	CHAPTER INTRODUCTION:	79
	What does the paper add to existing knowledge?.....	79
	What insights does the paper provide for informing health care-related decision-making?.....	79
4.2	ABSTRACT:	81
	Background:	81

Methods:.....	81
Results:.....	81
Conclusion:.....	82
4.3 INTRODUCTION:	83
4.4 METHODS:	84
4.4.1 <i>Patients and setting:</i>	84
4.4.2 <i>Study design and definitions:</i>	86
4.4.3 <i>Data analysis:</i>	87
4.5 RESULTS:	88
4.5.1 <i>Patient characteristics and duration of support:</i>	88
4.5.2 <i>Hospitalisation:</i>	89
4.5.3 <i>Admissions:</i>	91
4.5.4 <i>Index admission:</i>	93
4.6 DISCUSSION:.....	93
4.6.1 <i>Limitations:</i>	95
4.7 CONCLUSIONS:	96
4.8 CHAPTER CONCLUSION:.....	96
4.9 REFERENCES:	97

CHAPTER 5 COSTS BEFORE AND AFTER LEFT VENTRICULAR ASSIST DEVICE IMPLANT AND

PRECEDING HEART TRANSPLANT: A COHORT STUDY 101

5.1 CHAPTER INTRODUCTION.....	101
What does the paper add to existing knowledge?.....	101
What insights does the paper provide for informing health care-related decision-making?.....	102
5.2 ABSTRACT:	103
Background:	103
Methods:.....	103
Results:.....	103
Conclusion:.....	103
5.3 INTRODUCTION:	104

5.4	METHODS:	105
5.4.1	<i>Medical and nursing activity:</i>	<i>107</i>
5.4.2	<i>Indirect cost:</i>	<i>107</i>
5.4.3	<i>Linked administrative data:</i>	<i>107</i>
5.5	RESULTS:	108
5.5.1	<i>Patient presentations and outcomes.....</i>	<i>108</i>
5.5.2	<i>Costs:</i>	<i>110</i>
5.5.3	<i>Per diem cost:</i>	<i>111</i>
5.5.4	<i>Costs by resource centre:.....</i>	<i>115</i>
5.6	DISCUSSION:	115
5.6.1	<i>Limitations:</i>	<i>118</i>
5.7	CONCLUSIONS:	118
5.8	CHAPTER CONCLUSION:	118
5.9	REFERENCES:	120

**CHAPTER 6 EXAMINING DISCREPANCIES BETWEEN CLINICIAN PROXY ESTIMATES AND PATIENT
REPORTED QUALITY OF LIFE IN HEART FAILURE: MIND THE PRQOL GAP BETWEEN PATIENT AND
CLINICIAN. 125**

6.1	CHAPTER INTRODUCTION:	125
	What does the paper add to existing knowledge?.....	126
	What insights does the paper provide for informing health care-related decision-making?.....	126
	CITATION:	126
6.2	ABSTRACT:	127
	Background:	127
	Objective:	127
	Methods:	127
	Results:	127
	Conclusion:	127
6.3	INTRODUCTION:	128
6.4	METHODS:	130

6.4.1	<i>Sample:</i>	130
6.4.2	<i>Measures:</i>	130
6.4.3	<i>Statistical methods and Analyses:</i>	131
6.5	RESULTS:	132
6.5.1	<i>Patient characteristics:</i>	132
6.5.2	<i>Mean difference in overall utility scores:</i>	134
6.5.3	<i>Correlations:</i>	135
6.5.4	<i>Agreement:</i>	136
6.5.5	<i>Patient factors affecting the inter-rater gap (IRG):</i>	136
6.5.6	<i>Clinician factors affecting the inter-rater gap (IRG):</i>	137
6.5.7	<i>EQ5D 5L Domain level severity effects on the inter-rater gap:</i>	139
6.6	DISCUSSION:	140
6.7	LIMITATIONS:	143
6.8	CONCLUSIONS:	144
6.9	REFERENCES:	146
CHAPTER 7	IMPLICATIONS FOR POLICY, PRACTICE, EDUCATION AND RESEARCH	151
7.1	INTRODUCTION:	151
7.2	POLICY:	153
7.3	PRACTICE:	154
7.4	EDUCATION:	155
7.5	RESEARCH:	156
7.6	LIMITATIONS:	157
7.7	CONCLUSION:	158
7.8	REFERENCES:	159
APPENDICES:		163
	Appendix 1 Published methods PDF 1	163
	Appendix 2 Published hospitalisation PDF 2	164
	Appendix 3 Published cost PDF 3	165

Appendix 4 submitted proxy QoL PDF 4	166
Appendix 5 Coded costed medical/nursing activities identified in reviews and interviews	167
Appendix 6 Ar-DRG grouping codes for figure 4.5	171
Appendix 7. Additional median data table and figures for Chapter 4.....	173
Appendix 8: Heart failure care pathway	176
Appendix 9: Study cohort demographics and haemodynamics comparison with consecutively implanted VAD patients at the same site.	177
Appendix 10. Abstracts accepted for oral presentation	178
Appendix 11. Abstracts accepted for poster presentation	181

NB: Throughout this thesis table and figure numbers have been updated from their original published version so as to maintain sequential appearance throughout the document. Typographical errors in the published scripts have been corrected in the chapters and common abbreviations synchronised across the papers. Data mentioned in the text of Chapter 4 but not in published tables has been added as Appendix 7.

Finally reference lists have been updated to include chapter introductions and chapter conclusions, as well as operational URLs.

1.5 List of Tables:

TABLE 2-1 PUBMED AND MEDLINE SEARCH STRATEGY AND RESULTS	24
TABLE 2-2: REVIEWED PAPERS WITH COST AND UTILITY DATA SOURCES.....	26
TABLE 2-3 STUDY TYPE BY COSTING METHOD.....	37
TABLE 3-1 RESOURCES, SOURCES AND ISSUES	57
TABLE 3-2 EMERGENCY DEPARTMENT TRIAGE LEVEL COST WEIGHTS	64
TABLE 3-3 COSTS FOR VAD PATIENTS OVER PERIOD OF IMPLANTING ADMISSION (INCLUDES CONTIGUOUS EXTERNAL ADMISSIONS)	68
TABLE 4-1: DEMOGRAPHICS AND CLINICAL DATA.....	88
TABLE 4-2: VAD ADMISSION AND OUTLIER DAYS.....	91
TABLE 4-3: INPATIENT DAYS AND ADMISSIONS, EXCLUDING VAD ADMISSION.....	93
TABLE 5-1: DEMOGRAPHICS AND CLINICAL DATA.....	110
TABLE 5-2: PRE TRANSPLANT, PRE AND POST VAD, COHORT DAYS AND COSTS PER RESOURCE	113
TABLE 5-3: YEAR PRE AND POST VAD SHOWING THE IMPLANT ADMISSION SPLIT AT DATE OF SURGERY.....	114
TABLE 6-1: PATIENT CHARACTERISTICS	133
TABLE 6-2: CLINICIAN CHARACTERISTICS	133
TABLE 6-3: BINARY PATIENT FACTOR EFFECTS ON UTILITY SCORE.....	134
TABLE 6-4: CORRELATION AND BIAS RESULTS FOR UTILITY SCORES AND THE 5 EQ5D 5L DOMAINS.....	136
TABLE 6-5: WEIGHTED KAPPA ANALYSES FOR EQ5D 5L DOMAINS	136
TABLE 6-6 CHANGE IN THE INTER RATER GAP BY PATIENT FACTORS.....	137
TABLE 6-7:CLINICIAN FACTORS ASSOCIATED WITH SIZE OF THE INTER RATER GAP.....	139
TABLE 6-8: EFFECT OF REPORTED PROBLEMS AT THE DOMAIN LEVEL ON THE INTER-RATER GAP	140
TABLE 6-9: REGRESSION OF SIGNIFICANT CLINICIAN AND PATIENT FACTORS ON THE INTER-RATER GAP.....	140

1.6 List of Figures

FIGURE 1-1 CLINICAL COURSE OF HEART FAILURE WITH TRANSITION TO ADVANCED HEART FAILURE.....	6
FIGURE 1-2: AUSTRALIAN HEALTH SYSTEM AREAS OF EXPENDITURE AND SOURCES OF FUNDING	11
FIGURE 1-3 ICER EQUATION	12
FIGURE 1-4 VBHC EQUATION	13
FIGURE 1-5 OVERALL THESIS STRUCTURE	16
FIGURE 2-1 COST AND UTILITY DATA SOURCES LITERATURE REVIEW PRISMA FLOW CHART.....	25
FIGURE 2-2 ACCURACY IN MICRO AND GROSS-COSTING. ADAPTED WITH PERMISSION (53).....	33
FIGURE 3-1: BRIDGE TO TRANSPLANT VAD PATIENT PATHWAY WITH DECISION POINTS, CHRONIC AND ACUTE REFERRAL PATHWAYS.	53
FIGURE 3-2 COHORT INCLUSION AND EXCLUSION CRITERIA	55
FIGURE 3-3 BLAND ALTMAN ANALYSES OF PER DIEM MEAN MODELLED LOW- COST ACTIVITIES AGAINST OBSERVED RESULTS FROM DETAILED FILE REVIEWS.	65
FIGURE 3-4 BLAND ALTMAN ANALYSES OF PER DIEM MEDIAN MODELLED LOW- COST ACTIVITIES AGAINST OBSERVED RESULTS FROM DETAILED FILE REVIEWS	65
FIGURE 3-5: IMPLANTING COSTS DERIVED FROM INSTITUTIONAL MICRO-COSTING COMPARED WITH APDC DATA	66
FIGURE 4-1 INCLUSION CRITERIA AND OUTCOMES.....	85
FIGURE 4-2: MEDIAN % TIME SPENT AS AN INPATIENT UNTIL IMPLANT, TRANSPLANT OR DEATH.....	89
FIGURE 4-3: ADMISSION CATEGORY FREQUENCIES, PRE AND POST VAD IMPLANT.....	90
FIGURE 4-4: PROPORTION OF COHORT HOSPITALISED IN YEAR PRE AND POST VAD IMPLANT.....	92
FIGURE 5-1: INCLUSION AND EXCLUSION FLOW CHART WITH COHORT OUTCOMES.....	106
FIGURE 5-2: COST PER DAY AT RISK.	112
FIGURE 5-3: TOTAL PROPORTIONAL RESOURCE USE OVER EACH TIME PERIOD	115
FIGURE 6-1 CLINICIANS INCREASINGLY OVERESTIMATE QoL AS REPORTED QoL WORSENS.....	135
FIGURE 6-2: CLINICIAN AND PATIENT FACTORS AFFECTING THE INTER-RATER GAP-A-E.....	138
FIGURE 7-1: VALUE-BASED HEALTH CARE FRAMEWORK- (ADAPTED WITH PERMISSION FROM PORTER ET AL 2009).	156
FIGURE 0-1: IMPROVEMENT IN OUT OF HOSPITAL TIME FOR PATIENTS WITH VADs IN SECOND YEAR AFTER IMPLANT	174
FIGURE 0-2 COMPARING % TIME SPENT OUT OF HOSPITAL ACROSS THE COHORTS	175

1.7 List of Appendices:

APPENDIX 1 PUBLISHED METHODS PDF 1.....	163
APPENDIX 2 PUBLISHED HOSPITALISATION PDF 2.....	164
APPENDIX 3 PUBLISHED COST PDF 3	165
APPENDIX 4 SUBMITTED PROXY QOL PDF 4.....	166
APPENDIX 5 CODE AND COSTED MEDICAL AND NURSING ACTIVITIES IDENTIFIED IN REVIEWS AND INTERVIEWS	167
APPENDIX 6 AR-DRG GROUPING CODES FOR FIGURE 4.5.....	171
APPENDIX 7. ADDITIONAL MEDIAN DATA TABLE AND FIGURES FOR CHAPTER 4.....	173
APPENDIX 8. ABSTRACTS ACCEPTED FOR ORAL PRESENTATION.....	178

1.8 Acronyms and Abbreviations:

A10Z	ArDRG code for ventricular assist device implantation admission
ABF	Activity based funding
ACT	Australian Capital Territory
AHF	Advanced heart failure
AMI	Acute myocardial infarction
ANZCOTR	Australia and New Zealand Cardiothoracic Organ Transplant Registry
APDC	Admitted patient data collection (Australia)
ArDRG	Australian refined diagnosis related group
BiVAD	Biventricular assistance
BMI	Body mass index
BTC	Bridge to candidacy
BTT	Bridge to transplant
BTT-VAD	Bridge to transplant ventricular assist device
C-Pulse	Extra aortic counter pulsation device
CCL	Cardiac catheter laboratory
CCU	Coronary Care Unit
CEA	Cost effectiveness analysis
cf-VAD	Continuous flow ventricular assist device
CHeReL	Centre for Health Record Linkage (Australia)
CTCR	Cost to charge ratio
CUA	Cost utility analysis
DALY	Disability adjusted life year
DFR	Detailed file review
DMI 10	Depression in the medically ill questionnaire

DRG	Diagnosis related group
DT	Destination therapy
DT-VAD	Destination therapy ventricular assist device
ECMO	Extra corporeal membrane oxygenation
ED	Emergency department
EDDC	Emergency department data collection (Australia)
eGFR	Estimated glomerular filtration rate
EQ5D 5L	Euroqol five domains, five levels
EUROMACs	European Registry for Patients with Mechanical Circulatory Support
HF	Heart failure
HFpEF	Heart failure with preserved ejection fraction
HM2	Heartmate 2 VAD
HM3	Heartmate 3 VAD
HRQoL	Health related quality of life
HTA	Health technology assessment
HTx	Heart transplantation
HW	Heartware VAD
IC	Impaired cognition
ICD	International classification of disease
ICER	Incremental cost effectiveness ratio
ICU	Intensive care unit
IDMT	Inotrope dependent medical therapy
IHD	Ischaemic heart disease
IHPA	Independent Hospital Pricing Authority
IMACs	International Society for Heart and Lung Transplantation Mechanically Assisted Circulatory Support registry
INTERMACs	Interagency Registry for Mechanically Assisted Circulatory Support

IQR	Interquartile range
IRG	Inter rater gap
J-MACs	Japanese registry for mechanical assisted circulatory support
LOS	Length of stay
LVAD	Left ventricular assist device
MBS	Medical benefits scheme (Australia)
MoCA	Montreal cognitive assessment
MPAP	Mean pulmonary arterial pressure
MSAC	Medical Services Advisory Committee
NEP	National efficient price
NHCDC	National hospital cost data collection (Australia)
NHS	National Health Service (UK)
NIS	National inpatient sample (US)
NSW	New South Wales
NWAU	National weighted activity unit
NYHA	New York Heart Association
OMM	Optimal medical management
OOH	Out of hospital time
PAWP	Pulmonary arterial wedge pressure
PMSI	Program for the medicalisation of information systems (France)
PRO	Patient reported outcome
PROM	Patient reported outcome measure
prQoL	Patient reported quality of life
QALY	Quality adjusted life year
QoL	Quality of Life
RVU	Relative value unit
TAH	Total artificial heart

TDABC	Time driven activity based costing
TGA	Therapeutic Goods Administration
TMS	Theatre management system
UK	United Kingdom
US	United States
VAD	Ventricular assist device
VBHC	Value Based Health Care

1.9 Abstract:

Heart failure is a common, costly and burdensome condition for individuals, health care systems and societies. Multiple innovations, both pharmacological and non-pharmacological, have transformed care for millions around the world. Ventricular assist devices (VADs), as one of these new technologies, have saved many lives and bridged many to transplantation, while improving quality of life. VAD registry and clinical trial data are providing a roadmap for clinicians in their effective and most appropriate use, but the implementation of evidence based interventions requires consideration of patient, provider and system characteristics.

Australia supports a system of universal health coverage, yet has challenges in ensuring equity of access to care. Complex and fragmented funding models challenge an integrated understanding of the total costs associated with care pathways. A number of regulatory, and comprehensive health technology assessment processes inform policy and funding, and costing methods specific to local care models, are critical to inform health services planning.

As health care systems around the world examine value-based funding models, understanding patient preferences is also important. Many clinical trials do not include comprehensive economic analyses nor consider incentives for, and barriers to achieving access across health systems and funding models.

Communicating the value of an intervention to improve quality of life, requires consideration of patient, provider and population preferences.

This thesis is comprised of a number of discrete yet linked studies that sought to address the following questions,

1. How can linked data be used to establish costs and hospitalisation across different institutions in the years preceding and following VAD implant?
2. What is the relationship between VAD therapy as a bridge to transplant and overall heart failure hospitalisation and management costs compared with medical management?
3. What are the direct costs of managing advanced heart failure and VAD therapy in a quaternary specialist heart failure centre?
4. Could proxy quality of life assessments provided by clinicians for their heart failure patients provide useful utility estimates?

Four studies were undertaken, and a brief statement of findings is given below.

Study 1: Methods:

Linked administrative data provides a useful adjunct source for imputing costs external to the implanting centre, and combined with institutional data can illuminate both the pathways to transplant referral and the hospital activity generated by patients experiencing the terminal phases of heart failure in the year prior to transplant, cf-VAD implant or death.

Study 2: Hospitalisation:

Higher pre-implant hospitalisation in VAD patients reflects higher clinical acuity and implant is significantly associated with reduced admissions, and hospitalisation once reconditioning has occurred.

Study 3: Costs:

Once discharged home VAD implant stabilises hospital costs compared with accelerating costs in the year preceding implant. A high proportion of the hospital costs in the pre-implant year occur outside the implanting centre and should be considered in economic models assessing the impact of VAD implant.

Study 4: Proxy Quality of Life:

Clinicians in our sample tend to overestimate prQoL in heart failure patients, with patient sex, depressed mood and measured frailty all worsening the inter rater gap

1.9.2 Implications for policy, practice, education and research.

This thesis has shown the power of data to enrich clinical decision-making, as well as ensure policy and funding decisions are strategic, evidence based and reflect the needs of patients, families, communities, and clinicians. Progressing value-based health care remains a challenge requiring a commitment to rigorous studies within the framework of economic evaluation. In establishing the comparator populations, future cost effectiveness studies investigating VADs in advanced heart failure, should consider the costs and hospitalisations accrued at institutions other than the implanting centre. Formal screening for quality of life in this cohort would support reimbursement decisions and enhance shared decision-making in heart failure with real world patient reported outcomes data. Such data could impact patient selection, pre- conditioning pathways and the timing of implantation which could all impact the cost and effectiveness of ventricular assist device therapy in advanced heart failure.